While Rocket Pharmaceuticals Inc has overperformed by 1.37%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RCKT fell by -79.22%, with highs and lows ranging from $26.98 to $5.10, whereas the simple moving average fell by -65.97% in the last 200 days.
On March 12, 2025, BMO Capital Markets started tracking Rocket Pharmaceuticals Inc (NASDAQ: RCKT) recommending Outperform. A report published by Wedbush on December 30, 2024, Initiated its previous ‘Outperform’ rating for RCKT. Jefferies also rated RCKT shares as ‘Buy’, setting a target price of $29 on the company’s shares in an initiating report dated December 18, 2024. Goldman initiated its ‘Neutral’ rating for RCKT, as published in its report on April 02, 2024. Cantor Fitzgerald’s report from October 24, 2023 suggests a price prediction of $65 for RCKT shares, giving the stock a ‘Overweight’ rating. Morgan Stanley also rated the stock as ‘Overweight’.
Analysis of Rocket Pharmaceuticals Inc (RCKT)
Rocket Pharmaceuticals Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -54.14% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.30, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and RCKT has an average volume of 1.82M. On a monthly basis, the volatility of the stock is set at 7.53%, whereas on a weekly basis, it is put at 11.15%, with a loss of -22.19% over the past seven days. Furthermore, long-term investors anticipate a median target price of $40.53, showing growth from the present price of $5.19, which can serve as yet another indication of whether RCKT is worth investing in or should be passed over.
How Do You Analyze Rocket Pharmaceuticals Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 7.18%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 101.05% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RCKT shares are owned by institutional investors to the tune of 101.05% at present.
